Electra Therapeutics (NASDAQ:ETRA) Director Buys $19,999,995.00 in Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc acquired 1,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was bought at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the purchase, the director owned 5,126,891 shares in the company, valued at $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Electra Therapeutics Price Performance

NASDAQ ETRA opened at $11.55 on Friday. Electra Therapeutics, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $15.50.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research report on Saturday.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc is a clinical-stage biopharmaceutical company developing therapies for severe immune-mediated diseases. The company is focused on creating treatments designed to selectively remove disease-causing immune cells while preserving healthy immune cells.

Electra’s lead product candidate, ELA026, is an investigational antibody being developed for conditions involving harmful immune-cell activity. The company is evaluating the candidate in clinical studies for diseases including systemic sclerosis and immune thrombocytopenia.

Electra Therapeutics is headquartered in the United States and is focused primarily on advancing its pipeline through clinical development.